Selective Estrogen Receptor Modulators: An Update on Recent Clinical Findings
暂无分享,去创建一个
Wendy Shelly | R. Jaffe | V. Krishnan | Michael W. Draper | Venkatesh Krishnan | Mayme Wong | Robert B. Jaffe | M. Wong | M. Draper | W. Shelly | Mayme Wong
[1] N Rifai,et al. Differential effects of E and droloxifene on C-reactive protein and other markers of inflammation in healthy postmenopausal women. , 2001, The Journal of clinical endocrinology and metabolism.
[2] J Cuzick,et al. Overview of the main outcomes in breast-cancer prevention trials , 2003, The Lancet.
[3] P. Goss,et al. Aromatase inhibitors and bone health in women with breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] B. Katzenellenbogen,et al. Biomedicine. Defining the "S" in SERMs. , 2002, Science.
[5] J. Forbes,et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. , 2005, The New England journal of medicine.
[6] L. Ford,et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. , 2005, Journal of the National Cancer Institute.
[7] P. Neven,et al. Comparing raloxifene with continuous combined estrogen-progestin therapy in postmenopausal women: Review of Euralox 1. , 2005, Maturitas.
[8] A. Díez-Pérez,et al. Anti-vertebral fracture efficacy of raloxifene: a meta-analysis , 2006, Osteoporosis International.
[9] D. Irvine,et al. The effect of three anti-oestrogen drugs on cervical mucus quality and in-vitro sperm-cervical mucus interaction in ovulatory women. , 1993, Human reproduction.
[10] I. Reid,et al. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women. , 2004, Archives of internal medicine.
[11] S. Cummings,et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. , 2004, Journal of the National Cancer Institute.
[12] G. Gormley. Chemoprevention strategies , 2022 .
[13] R. Tracy,et al. Role of tumor necrosis factor-alpha and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women. , 2001, The American journal of cardiology.
[14] P. Neven,et al. Uterine Effects of Estrogen Plus Progestin Therapy and Raloxifene: Adjudicated Results From the EURALOX Study , 2004, Obstetrics and gynecology.
[15] B. Walsh,et al. A 12‐Month Comparative Study of Raloxifene, Estrogen, and Placebo on the Postmenopausal Endometrium , 2000, Obstetrics and gynecology.
[16] P. Härkönen,et al. Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women , 2005, Menopause.
[17] R B Mazess,et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. , 1992, The New England journal of medicine.
[18] S. Majumdar,et al. High-resolution MRI and micro-FE for the evaluation of changes in bone mechanical properties during longitudinal clinical trials: application to calcaneal bone in postmenopausal women after one year of idoxifene treatment. , 2002, Clinical biomechanics.
[19] E. Kolibianakis,et al. Endometrial thickness cannot predict ongoing pregnancy achievement in cycles stimulated with clomiphene citrate for intrauterine insemination. , 2004, Reproductive biomedicine online.
[20] J. Heikkinen,et al. Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women , 2004, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.
[21] P. Neven,et al. A multicentre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing oestradiol and norethisterone acetate , 2003, BJOG : an international journal of obstetrics and gynaecology.
[22] M. Mayo,et al. Breast Cancer Chemoprevention Phase I Evaluation of Biomarker Modulation by Arzoxifene, a Third Generation Selective Estrogen Receptor Modulator , 2004, Clinical Cancer Research.
[23] J. Reginster,et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. , 2002, The Journal of clinical endocrinology and metabolism.
[24] P. Lønning,et al. Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial , 2007, The Lancet.
[25] S. Cummings,et al. Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. , 2005, The American journal of psychiatry.
[26] C. Gong,et al. A double-blind randomized controlled trial of toremifen therapy for mastalgia. , 2006, Archives of surgery.
[27] S. Cummings,et al. Safety and Adverse Effects Associated With Raloxifene: Multiple Outcomes of Raloxifene Evaluation , 2004, Obstetrics and gynecology.
[28] C. Arnaud,et al. A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[29] Mike Clarke,et al. Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.
[30] H. Harvey,et al. Toremifene: an evaluation of its safety profile. , 2006, Breast.
[31] P. Neven,et al. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years , 2003, Menopause.
[32] D. Bostwick,et al. Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial. , 2006, The Journal of urology.
[33] P. Neven,et al. Raloxifene Effect on Frequency of Surgery for Pelvic Floor Relaxation , 2001, Obstetrics and gynecology.
[34] K. Korach,et al. Potential Biological Functions Emerging from the Different Estrogen Receptors , 2006, Annals of the New York Academy of Sciences.
[35] L. Kuller,et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. , 1998, JAMA.
[36] D. Wickerham. Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene , 2005 .
[37] G. Lyman,et al. Serum cholesterol reduction with tamoxifen , 1990, Breast Cancer Research and Treatment.
[38] V. Vogel. Chemoprevention Strategies 2006 , 2007, Current treatment options in oncology.
[39] W. Chin,et al. Molecular and Clinical Evidence for the Unique Nature of Individual Selective Estrogen Receptor Modulators , 2003, Clinical obstetrics and gynecology.
[40] S. Taneja,et al. Toremifene – a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy , 2006, Expert opinion on investigational drugs.
[41] Y. Qu,et al. The effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and six months: a secondary analysis of the MORE trial , 2005, Current medical research and opinion.
[42] J. Roy,et al. Activity and safety of the antiestrogen EM-800, the orally active precursor of acolbifene, in tamoxifen-resistant breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] C. Niederberger,et al. Clomiphene administration for cases of nonobstructive azoospermia: a multicenter study. , 2005, Journal of andrology.
[44] B. Katzenellenbogen,et al. Defining the "S" in SERMs , 2002, Science.
[45] P. Munster. Arzoxifene: the development and clinical outcome of an ideal SERM , 2006, Expert opinion on investigational drugs.
[46] J. Pike,et al. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. , 1995, Molecular endocrinology.
[47] D. McDonnell,et al. The molecular pharmacology of estrogen receptor modulators: implications for the treatment of breast cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[48] B. Komm,et al. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. , 2005, Endocrinology.
[49] S. Cummings,et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. , 1999, JAMA.
[50] M. Freedman,et al. Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo. , 2001, Journal of the National Cancer Institute.
[51] H. Depypere,et al. Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study , 2001, Climacteric : the journal of the International Menopause Society.
[52] T. Luukkaala,et al. Toremifene for premenstrual mastalgia: a randomised, placebo‐controlled crossover study , 2006, BJOG : an international journal of obstetrics and gynaecology.
[53] V. Jackson,et al. Comparison of the effect of raloxifene and continuous-combined hormone therapy on mammographic breast density and breast tenderness in postmenopausal women. , 2003, American journal of obstetrics and gynecology.
[54] S. Martino,et al. Safety assessment of raloxifene over eight years in a clinical trial setting* , 2005, Current medical research and opinion.
[55] F. Cosman. Selective estrogen-receptor modulators. , 2003, Clinics in geriatric medicine.
[56] J. Cuzick,et al. Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. , 2007, Journal of the National Cancer Institute.
[57] J. Costantino,et al. Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial. , 2005, American journal of obstetrics and gynecology.
[58] M. Soules,et al. Comparison of basal follicle-stimulating hormone versus the clomiphene citrate challenge test for ovarian reserve screening. , 2004, Fertility and sterility.
[59] H. Genant,et al. Effects of Raloxifene on Fracture Severity in Postmenopausal Women with Osteoporosis: Results from the MORE Study , 2002, Osteoporosis International.
[60] T. Powles,et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] H. Iwase,et al. [Breast cancer]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.
[62] J. Forbes,et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] J. Reginster,et al. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. , 2004, Bone.
[64] Anthony Howell,et al. Pure oestrogen antagonists for the treatment of advanced breast cancer. , 2006, Endocrine-related cancer.
[65] J. Cauley,et al. Effects of Raloxifene on Fracture Risk in Postmenopausal Women: The Raloxifene Use for The Heart Trial , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[66] A. Badawy,et al. Clomiphene citrate or letrozole for ovulation induction in women with polycystic ovarian syndrome: a prospective randomized trial. , 2009, Fertility and sterility.
[67] P. Kenemans,et al. Raloxifene reduces procarboxypeptidase U, an antifibrinolytic marker. A 2-year randomized, placebo-controlled study in healthy early postmenopausal women , 2004, Menopause.
[68] B. Bonanni,et al. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. , 2007, Journal of the National Cancer Institute.
[69] L. Plouffe,et al. Uterine Effects of 3‐Year Raloxifene Therapy in Postmenopausal Women Younger Than Age 60 , 2000, Obstetrics and gynecology.
[70] E. Barrett-Connor,et al. Year-by-year analysis of cardiovascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial* , 2005, Current medical research and opinion.
[71] W. Schoonen,et al. Receptor profiling and endocrine interactions of tibolone , 2003, Steroids.
[72] B. Mol,et al. The clomiphene citrate challenge test for the prediction of poor ovarian response and nonpregnancy in patients undergoing in vitro fertilization: a systematic review. , 2006, Fertility and sterility.
[73] G. Sledge,et al. Effects of high dose raloxifene in selected patients with advanced breast carcinoma , 2000, Cancer.
[74] S. Goldstein,et al. Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study. , 2002, American journal of obstetrics and gynecology.
[75] M Baum,et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial , 2002, The Lancet.
[76] S. Goldstein. The Effect of SERMs on the Endometrium , 2001, Annals of the New York Academy of Sciences.
[77] W. Riley,et al. Cardiovascular effects of droloxifene, a new selective estrogen receptor modulator, in healthy postmenopausal women. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[78] J. Thomsen,et al. Mechanisms of estrogen action. , 2001, Physiological reviews.
[79] C K Redmond,et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.
[80] T. Bourne,et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial , 1994, The Lancet.
[81] C. Christiansen,et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. , 1997, The New England journal of medicine.
[82] J. Reginster,et al. Relationship Between Changes in Biochemical Markers of Bone Turnover and BMD to Predict Vertebral Fracture Risk , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[83] T. Powles,et al. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. , 2007, Journal of the National Cancer Institute.
[84] R. Elledge,et al. Idoxifene versus tamoxifen: a randomized comparison in postmenopausal patients with metastatic breast cancer. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[85] B. L. Riggs,et al. Bone Turnover Matters: The Raloxifene Treatment Paradox of Dramatic Decreases in Vertebral Fractures Without Commensurate Increases in Bone Density , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[86] J. Scott,et al. Raloxifene: a selective estrogen receptor modulator. , 1999, American family physician.
[87] P. Boyle,et al. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. , 2003, Journal of the National Cancer Institute.
[88] O. Johnell,et al. Associations Between Baseline Risk Factors and Vertebral Fracture Risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[89] E. Barrett-Connor,et al. Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis. , 2006, The American journal of cardiology.
[90] N. Sugino,et al. Effects of clomiphene citrate on the endometrial thickness and echogenic pattern of the endometrium. , 1997, Fertility and sterility.
[91] S. Cummings,et al. Effect of Raloxifene on Urinary Incontinence: A Randomized Controlled Trial , 2004, Obstetrics and gynecology.
[92] T. Powles,et al. The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[93] S. Reis,et al. Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators. , 2001, Journal of the National Cancer Institute.
[94] R. Karas,et al. The protective effects of estrogen on the cardiovascular system. , 2002, The New England journal of medicine.
[95] S. Cummings,et al. Skeletal Effects of Raloxifene After 8 Years: Results from the Continuing Outcomes Relevant to Evista (CORE) Study , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[96] B. Walsh. The Effects of Estrogen and Selective Estrogen Receptor Modulators on Cardiovascular Risk Factors , 2001, Annals of the New York Academy of Sciences.
[97] P. Torng,et al. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients. , 1997, Gynecologic oncology.
[98] S. Cummings,et al. Effect of Raloxifene on the Incidence of Invasive Breast Cancer in Postmenopausal Women with Osteoporosis Categorized by Breast Cancer Risk , 2006, Clinical Cancer Research.
[99] O. Johnell,et al. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. , 2002, The Journal of clinical endocrinology and metabolism.
[100] N. Watts,et al. Incidence of urinary incontinence in postmenopausal women treated with raloxifene or estrogen , 2005, Menopause.
[101] P. Kenemans,et al. The effects of 12 weeks of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis: a randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women. , 2005, American journal of obstetrics and gynecology.
[102] P. Sabbatini,et al. A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer. , 2003, Gynecologic oncology.
[103] M. Sporn. Arzoxifene: A Promising New Selective Estrogen Receptor Modulator for Clinical Chemoprevention of Breast Cancer , 2004, Clinical Cancer Research.
[104] W. Huster,et al. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. , 1997, American journal of obstetrics and gynecology.
[105] L. F. Chasseaud,et al. Pharmacokinetics and metabolism of the anti-oestrogen droloxifene in female human subjects , 2002, Xenobiotica; the fate of foreign compounds in biological systems.
[106] P. Neven,et al. The effect of raloxifene on the incidence of ovarian cancer in postmenopausal women , 2002, Gynecologic oncology.
[107] S. Corson. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes , 2006 .
[108] Robert Marcus,et al. Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women , 2003, Osteoporosis International.
[109] D. Holtkamp,et al. Development, pharmacology and clinical experience with clomiphene citrate. , 1996, Human reproduction update.
[110] V. Jordan,et al. Chemoprevention of breast cancer with selective oestrogen-receptor modulators , 2007, Nature Reviews Cancer.
[111] Myles Brown,et al. Cofactor Dynamics and Sufficiency in Estrogen Receptor–Regulated Transcription , 2000, Cell.
[112] J. Heikkinen,et al. Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial , 2003, Menopause.
[113] R. Casper,et al. Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. , 2006, Fertility and sterility.
[114] K Yaffe,et al. Cognitive function in postmenopausal women treated with raloxifene. , 2001, The New England journal of medicine.
[115] M. Cotreau,et al. Multiple‐Dose, Safety, Pharmacokinetics, and Pharmacodynamics of a New Selective Estrogen Receptor Modulator, ERA‐923, in Healthy Postmenopausal Women , 2002, Journal of clinical pharmacology.
[116] B. Mitlak,et al. Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women. , 1999, Menopause.
[117] T. Vogelvang,et al. HMR 3339, a novel selective estrogen receptor modulator, reduces concentrations of procarboxypeptidase U, an inhibitor of fibrinolysis. A randomized, placebo‐controlled study in postmenopausal women , 2005, Journal of thrombosis and haemostasis : JTH.
[118] S. Goldstein. Not all SERMs are created equal. , 2006, Menopause.
[119] R. Tracy,et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. , 2000, The Journal of clinical endocrinology and metabolism.
[120] J. Heikkinen,et al. Effects of ospemifene, a novel SERM, on vascular markers and function in healthy, postmenopausal women , 2003, Menopause.
[121] U. Hellmann-Blumberg,et al. Genotoxic effects of the novel mixed antiestrogen FC-1271a in comparison to tamoxifen and toremifene , 2000, Breast Cancer Research and Treatment.
[122] H. Hollema,et al. TAMOXIFEN TREATMENT AND GYNECOLOGIC SIDE EFFECTS: A REVIEW , 2001, Obstetrics and gynecology.
[123] I. Pávó,et al. The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis. , 2006, The Journal of clinical endocrinology and metabolism.
[124] Luigi Gennari. Ospemifene Hormos. , 2004, Current opinion in investigational drugs.
[125] J. E. Johnson,et al. Further clinical experience with clomiphene citrate. , 1968, Fertility and sterility.
[126] I. Reid,et al. The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. , 1995, The Journal of clinical endocrinology and metabolism.
[127] D. Black,et al. Relationships Between Bone Mineral Density and Incident Vertebral Fracture Risk with Raloxifene Therapy , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[128] P. Frost,et al. Combination therapy for treating breast cancer using antiestrogen, ERA-923, and the mammalian target of rapamycin inhibitor, temsirolimus. , 2006, Endocrine-related cancer.
[129] M Baum,et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer , 2005, The Lancet.
[130] S. Cummings,et al. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene , 2006, Menopause.
[131] C. Sansotta,et al. Effect of long-term treatment with raloxifene on mammary density in postmenopausal women , 2006, Menopause.
[132] A. Howell,et al. A Cancer Research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen , 2004, Cancer Chemotherapy and Pharmacology.
[133] H. Genant,et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. , 2003, Bone.
[134] David A. Agard,et al. The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.
[135] H. Doihara,et al. Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids , 2004, Breast Cancer Research and Treatment.
[136] I. Reid,et al. The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. , 1995, The American journal of medicine.
[137] B. Riggs,et al. The actions and interactions of sex steroids and growth factors/cytokines on the skeleton. , 1999, Molecular endocrinology.
[138] S. Goldstein. Not all selective estrogen response modulators are created equal: update on lasofoxifene. , 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
[139] Harry K. Genant,et al. Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-year Randomized Clinical Trial , 2000 .
[140] B. O’Malley,et al. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. , 1997, Molecular endocrinology.
[141] J. Robertson,et al. Fulvestrant: Pharmacologic Profile Versus Existing Endocrine Agents for the Treatment of Breast Cancer , 2006, The Annals of pharmacotherapy.
[142] P. Lips,et al. Bone Histomorphometric and Biochemical Marker Results of a 2‐Year Placebo‐Controlled Trial of Raloxifene in Postmenopausal Women , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[143] Myles Brown,et al. Molecular Determinants for the Tissue Specificity of SERMs , 2002, Science.
[144] David M. Heery,et al. A signature motif in transcriptional co-activators mediates binding to nuclear receptors , 1997, Nature.
[145] M. Singh. Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone‐related clinical disorders , 2001, Medicinal research reviews.
[146] J. Adachi,et al. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. , 2002, Archives of internal medicine.
[147] D. Leitman,et al. Selective estrogen receptor modulators in reproductive medicine and biology. , 2000, Obstetrical & gynecological survey.
[148] E. Ariazi,et al. Estrogen receptors as therapeutic targets in breast cancer. , 2006, Current topics in medicinal chemistry.
[149] C. Christiansen,et al. Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM) , 2004, Menopause.
[150] E. Barrett-Connor,et al. Adult Weight Change and Risk of Postmenopausal Breast Cancer , 2006, The New England journal of medicine.
[151] C. Farquhar,et al. Oral anti-oestrogens and medical adjuncts for subfertility associated with anovulation. , 2005, The Cochrane database of systematic reviews.
[152] D. Lurie,et al. The Effect of Consecutive Cycles of Clomiphene Citrate Therapy on Endometrial Thickness and Echo Pattern , 1995, Obstetrics and gynecology.
[153] C. Turner,et al. LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo. , 1998, The Journal of pharmacology and experimental therapeutics.
[154] F. Akercan,et al. Does raloxifene therapy affect mammographic breast cancer screening in postmenopausal patients? , 2006, European journal of gynaecological oncology.
[155] C. Christiansen,et al. What can be learned from the levormeloxifene experience? , 2006, Acta obstetricia et gynecologica Scandinavica.
[156] E. Adashi,et al. Gestational outcome of clomiphene-related conceptions. , 1979, Fertility and sterility.
[157] T. Powles,et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial , 1998, The Lancet.
[158] L. Gennari. Lasofoxifene: a new type of selective estrogen receptor modulator for the treatment of osteoporosis. , 2006, Drugs of Today.
[159] R. Lilford,et al. Clomiphene or tamoxifen for idiopathic oligo/asthenospermia. , 1996, The Cochrane database of systematic reviews.
[160] P. Boyle,et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women , 1998, The Lancet.
[161] I. Cohen,et al. Endometrial changes with tamoxifen: comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients. , 1994, Gynecologic oncology.
[162] T. Powles,et al. Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial , 2004, Breast Cancer Research and Treatment.
[163] P. Kulkarni,et al. Vascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial: incidence, patient characteristics, and effect of raloxifene , 2005, Menopause.
[164] Z. Rosenwaks,et al. PROGNOSTIC ASSESSMENT OF FEMALE FECUNDITY , 1987, The Lancet.
[165] L. Plouffe,et al. Adverse events reported by postmenopausal women in controlled trials with raloxifene. , 1999, Obstetrics and gynecology.
[166] E. Vittinghoff,et al. Vitamin D insufficiency does not affect bone mineral density response to raloxifene. , 2005, The Journal of clinical endocrinology and metabolism.
[167] M. Gardner,et al. Clinical Pharmacology of Multiple Doses of Lasofoxifene in Postmenopausal Women , 2006, Journal of clinical pharmacology.
[168] L. Plouffe,et al. Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. , 2005, Obstetrics and gynecology.
[169] J. Cuzick,et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial , 2002, The Lancet.
[170] A. Howell. Fulvestrant ('Faslodex'): current and future role in breast cancer management. , 2006, Critical reviews in oncology/hematology.
[171] P. Lønning,et al. Phase III Randomized Trial of Droloxifene and Tamoxifen As First-Line Endocrine Treatment of ER/PgR-Positive Advanced Breast Cancer , 2002, Breast Cancer Research and Treatment.
[172] C. Christiansen,et al. Adverse effects of a SERM (Levormeloxifene). Safety parameters and bone mineral density 12 months after treatment withdrawal. , 2003, Maturitas.
[173] I Vergote,et al. Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[174] A. Nangia,et al. Select patients with hypogonadotropic hypogonadism may respond to treatment with clomiphene citrate. , 2006, Fertility and sterility.
[175] S. Palacios. The future of the new selective estrogen receptor modulators , 2007, Menopause international.
[176] S. Saarikoski,et al. Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women , 2006, Journal of Bone and Mineral Metabolism.
[177] Robert N Hoover,et al. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. , 2007, Journal of the National Cancer Institute.
[178] P. Albertazzi,et al. Urogenital effects of selective estrogen receptor modulators: a systematic review , 2005, Climacteric : the journal of the International Menopause Society.
[179] O. Johnell,et al. Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. , 2003, Bone.
[180] F. Cohen,et al. Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials. , 2000, Maturitas.